Sorafenib hepatobiliary disposition: Mechanisms of hepatic uptake and disposition of generated metabolites

Drug Metabolism and Disposition

Volumn 41, Issue 6, 2013, Pages 1179-1186

  Swift, Brandon ^a   Nebot, Noelia ^a   Lee, Jin Kyung ^a   Han, Tianxiang ^a   Proctor, William R ^a   Thakker, Dhiren R ^a   Lang, Dieter ^b   Radtke, Martin ^b   Gnoth, Mark J ^b   Brouwer, Kim L R ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CARBON SORAFENIB C 14; DECYNIUM 22; DRUG METABOLITE; KETOPROFEN; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; PROTEIN INHIBITOR; RADIOPHARMACEUTICAL AGENT; RIFAMYCIN; SORAFENIB; SORAFENIB GLUCURONIDE; SORAFENIB N OXIDE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL TRANSPORT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DISPOSITION; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; LIMIT OF DETECTION; LIVER CELL; LIVER METABOLISM; MALE; MICHAELIS CONSTANT; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PASSIVE DIFFUSION; PRIORITY JOURNAL; PROTEIN FUNCTION; SANDWICH CULTURE;

ADULT; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS;

EID: 84878254626     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048181     Document Type: Article

References (48)

1. Agarwal S, Sane R, Ohlfest JR, and Elmquist WF (2011) The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 336:223-233.
2. Baur H, Kasperek S, and Pfaff E (1975) Criteria of viability of isolated liver cells. Hoppe Seylers Z Physiol Chem 356:827-838.
3. Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, and Suter L (2003) Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 73:386-402.
4. Briz O, Romero MR, Martinez-Becerra P, Macias RI, Perez MJ, Jimenez F, San Martin FG, and Marin JJ (2006) OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J Biol Chem 281:30326-30335.
5. Cui Y, König J, Leier I, Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
6. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
7. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
8. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, and Lee CA (2009) Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173-181.
9. Ghassabian S, Rawling T, Zhou F, Doddareddy MR, Tattam BN, Hibbs DE, Edwards RJ, Cui PH, and Murray M (2012) Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochem Pharmacol 84:215-223.
10. Gnoth MJ, Sandmann S, Engel K, and Radtke M (2010) In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 38:1341-1346.
11. Hayer-Zillgen M, Brüss M, and Bönisch H (2002) Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136:829-836.
12. +-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem 279:7213-7222.
13. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
14. Hoen PA, Commandeur JN, Vermeulen NP, Van Berkel TJ, and Bijsterbosch MK (2000) Selective induction of cytochrome P450 3A1 by dexamethasone in cultured rat hepatocytes: analysis with a novel reverse transcriptase-polymerase chain reaction assay section sign. Biochem Pharmacol 60:1509-1518.
15. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, and Baker SD (2009) Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 15:6062-6069.
16. Ieiri I, Higuchi S, and Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-729.
17. Kamisako T, Leier I, Cui Y, König J, Buchholz U, Hummel-Eisenbeiss J, and Keppler D (1999) Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 30:485-490.
18. Koepsell H, Schmitt BM, and Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36-90.
19. König J, Cui Y, Nies AT, and Keppler D (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156-G164.
20. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, and Sundaresan P (2006) Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57:685-692.
21. Le Cluyse EL, Bullock PL, Parkinson A, and Hochman JH (1996) Cultured rat hepatocytes. Pharm Biotechnol 8:121-159.
22. +-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170-1178.
23. Li L, Meier PJ, and Ballatori N (2000) Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol 58:335-340.
24. Liu X, Le Cluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, and Brouwer K L R (1999) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12-G21.
25. Mahagita C, Grassl SM, Piyachaturawat P, and Ballatori N (2007) Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 293:G271-G278.
26. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, and Abe T (2004) The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19:171-179.
27. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, et al. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27:1800-1805.
28. Minematsu T and Giacomini KM (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10:531-539.
29. Ming X, Ju W, Wu H, Tidwell RR, Hall JE, and Thakker DR (2009) Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos 37:424-430.
30. Morita N, Kusuhara H, Sekine T, Endou H, and Sugiyama Y (2001) Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther 298:1179-1184.
31. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, and Terasaki T (2002) Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83:57-66.
32. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, and Xiong HQ, et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512.
33. Shibayama Y, Nakano K, Maeda H, Taguchi M, Ikeda R, Sugawara M, Iseki K, Takeda Y, and Yamada K (2011) Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull 34:433-435.
34. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
35. Soars MG, Webborn PJ, and Riley RJ (2009) Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol Pharm 6:1662-1677.
36. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, and Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426-437.
37. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, and Haase CG, et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972.
38. Sun W, Wu RR, Van Poelje PD, and Erion MD (2001) Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun 283:417-422.
39. Swift B, Yue W, and Brouwer K L R (2010) Evaluation of (99m) technetium-mebrofenin and (99m) technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes. Pharm Res 27:1987-1998.
40. Thomas J, Wang L, Clark RE, and Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739-3745.
41. Van Montfoort JE, Hagenbuch B, Fattinger KE, Müller M, Groothuis GM, Meijer DK, and Meier PJ (1999) Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther 291:147-152.
42. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
43. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, and McHugh M, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109.
44. Wolf KK, Brouwer KR, Pollack GM, and Brouwer K L R (2008) Effect of albumin on the biliary clearance of compounds in sandwich-cultured rat hepatocytes. Drug Metab Dispos 36:2086-2092.
45. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, and Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51:913-921.
46. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, and Baker SD (2013) Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenibglucuronide. Clin Cancer Res DOI: [published ahead of print].
47. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, and Trauner M (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38:717-727.
48. Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, and Trauner M (2007) Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 27:920-929.